[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651396":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":115,"collaborators":117,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":25,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":25,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":25,"overallStatus":138,"whyStopped":25,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Xinqiao Hospital of Chongqing","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tirofiban + Aspirin","EXPERIMENTAL","Aspirin 100 mg once daily orally for 90 days, plus immediate intravenous tirofiban after randomization: 0.4 µg\u002Fkg\u002Fmin for the first 30 minutes, then 0.1 µg\u002Fkg\u002Fmin for a total of 24 hours. Plus guideline-based standard care.",[13],"Drug: Tirofiban",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo + Aspirin","PLACEBO_COMPARATOR","Aspirin 100 mg once daily orally for 90 days, plus immediate intravenous tirofiban-matching placebo infusion (0.4 µg\u002Fkg\u002Fmin × 30 min, then 0.1 µg\u002Fkg\u002Fmin × 24 h) after randomization. Plus guideline-based standard care.",[19],"Drug: Tirofiban-matching placebo",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Tirofiban",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Tirofiban-matching placebo","Aspirin 100 mg once daily orally for 90 days, plus immediate intravenous tirofiban-matching placebo infusion (0.4 µg\u002Fkg\u002Fmin × 30 min, then 0.1 µg\u002Fkg\u002Fmin × 24 h). Plus guideline-based standard care.",[15],[31],{"name":32,"affiliation":33,"role":34},"Zhongming Qiu","Xinqiao Hospital of the Army Medical University","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Daojun Hong, MD","CONTACT","+8613879187691","hongdaojun@hotmail.com",{"name":42,"role":38,"phone":25,"phoneExt":25,"email":43},"Jing Lin, MD","linjingsys2016@126.com",[45,64,79,92,105],{"facility":46,"status":25,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"The First Affiliated Hospital of Hainan Medical University","Haikou","Hainan","570000","China","CN",{"type":53,"coordinates":54},"Point",[55,56],110.34651,20.03421,{"lat":56,"lon":55},[59,63],{"name":60,"role":38,"phone":61,"phoneExt":25,"email":62},"Zhenqiang Zhao","+86 13976015677","zhenqiang.zhao@qq.com",{"name":25,"role":38,"phone":25,"phoneExt":25,"email":40},{"facility":65,"status":25,"city":66,"state":67,"zip":68,"country":50,"countryCode":51,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"The First People's Hospital of Jingdezhen City","Jingdezhen","Jiangxi","341000",{"type":53,"coordinates":70},[71,72],117.20789,29.2947,{"lat":72,"lon":71},[75],{"name":76,"role":38,"phone":77,"phoneExt":25,"email":78},"Shunfu Jiang","+86 18907982686","shenli869@163.com",{"facility":80,"status":25,"city":81,"state":67,"zip":68,"country":50,"countryCode":51,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"The First People's Hospital of Jiujiang City","Jiujiang",{"type":53,"coordinates":83},[84,85],116.00206,29.70475,{"lat":85,"lon":84},[88],{"name":89,"role":38,"phone":90,"phoneExt":25,"email":91},"Tuanyuan Zheng","+86 13507925845","zty13507925845@163.com",{"facility":93,"status":25,"city":94,"state":67,"zip":68,"country":50,"countryCode":51,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"The First Affiliated Hospital of Gannan Medical University","Nanchang",{"type":53,"coordinates":96},[97,98],115.85306,28.68396,{"lat":98,"lon":97},[101],{"name":102,"role":38,"phone":103,"phoneExt":25,"email":104},"Qiujiang Xi","+86 18170868978","Xiqiujiang992437@sina.com",{"facility":106,"status":25,"city":94,"state":67,"zip":68,"country":50,"countryCode":51,"cosmosGeoPoint":107,"geoPoint":109,"contacts":110},"The First Affiliated Hospital of Nanchang University",{"type":53,"coordinates":108},[97,98],{"lat":98,"lon":97},[111,114],{"name":112,"role":38,"phone":113,"phoneExt":25,"email":40},"Daojun Hong","+86 13879187691",{"name":25,"role":38,"phone":25,"phoneExt":25,"email":40},{"type":34,"investigatorFullName":32,"investigatorTitle":116,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Professor",[118],{"name":106,"class":6},"100651396","phase-4-tirofiban-combined-with-aspirin-in-moderate-ischemic-stroke-100651396",false,"NCT07760922","Tirofiban Combined With Aspirin in Moderate Ischemic Stroke","Efficacy and Safety of Tirofiban Combined With Aspirin in Moderate Ischemic Stroke: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Acute ischemic stroke; time from last known well to randomization ≤ 24 hours;\n3. Pre-randomization NIHSS score 4-10, with at least one of item 5 (upper limb) or item 6 (lower limb) ≥ 1;\n4. Pre-stroke modified Rankin Scale (mRS) ≤ 1;\n5. Written informed consent provided by the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT or MRI;\n2. Has received or is planned to receive reperfusion therapy (thrombolysis or endovascular treatment);\n3. Any definite cardioembolic source: chronic\u002Fparoxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction \\\u003C 30%;\n4. Definite indication for anticoagulation (atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism);\n5. Severe systemic disease (e.g., severe infection, severe hepatic or renal dysfunction);\n6. Allergy to tirofiban and\u002For aspirin;\n7. History of intracranial hemorrhage;\n8. Planned use of NSAIDs affecting platelet function;\n9. Gastrointestinal bleeding or major surgery within the past 3 months;\n10. Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months;\n11. Planned surgery or intervention requiring discontinuation of antiplatelet therapy;\n12. Stroke caused by angiography or surgery;\n13. Prior non-atherosclerotic arterial disease, including moyamoya disease, arterial dissection, fibromuscular dysplasia;\n14. Other structural brain disease (vascular malformation, tumor, abscess, multiple sclerosis, etc.) confirmed by CT\u002FMRI;\n15. Pregnancy or lactation;\n16. Prior neurologic or psychiatric disease that would interfere with neurologic assessment;\n17. Participation in another clinical trial;\n18. Advanced disease with expected survival \\\u003C 6 months;\n19. Expected inability to complete follow-up.","ALL","18 Years","80 Years",{"count":130,"type":131},1168,"ESTIMATED","INTERVENTIONAL",[134],"PHASE4","Ischemic stroke accounts for the majority of stroke cases in China, and moderate ischemic stroke (NIHSS 4-10) carries a high risk of early neurologic deterioration (END) and long-term disability. Although intensified antiplatelet strategies reduce END, they have not consistently improved long-term functional outcome. Tirofiban, a selective glycoprotein IIb\u002FIIIa receptor inhibitor, has shown a clinically meaningful trend toward better 90-day functional outcome (mRS 0-1) in prior tirofiban trials, but existing sample sizes were underpowered to detect this difference.\n\nTAMIS is a multicenter, randomized, double-blind, placebo-controlled superiority trial in patients with acute moderate ischemic stroke (NIHSS 4-10) within 24 hours of last known well. Eligible patients are randomized 1:1 to tirofiban plus aspirin versus placebo plus aspirin, both on a background of guideline-based standard medical care. The primary efficacy endpoint is the proportion of patients with an excellent functional outcome (mRS 0-1) at 90 days. The primary safety endpoint is symptomatic intracranial hemorrhage within 48 (±12) hours by the Heidelberg criteria.",[137],"Ischemic Stroke, Acute","NOT_YET_RECRUITING","2026-08-07",{"date":141,"type":142},"2026-08-12","ACTUAL",{"date":144,"type":131},"2026-10-01",{"date":146,"type":131},"2028-12-31",{"name":5,"class":6},5]